FierceBiotech
Acticor halts phase 2/3 stroke trial for blood thinner over futility
Acticor Biotech is discontinuing a phase 2/3 study of a blood thinner given alongside heart surgery based on the results of a futility analysis. The French company had been testing the drug, ...
5 days ago